

HETERO LABS LIMITED

CIN: U24110AP1989PLC009723

Marketing Office:

607/608, Matharu Arcade, Plot No. 32, Subhash Road, Vile Parle (E), Mumbai - 400 057, India. Tel: 91 22 6691 0809 (6 Lines) • Fax: 91 22 2684 5709 • E-mail: contact@heterodrugs.com

September 22, 2015

Gilead Science, Inc. 333 Lakeside Drive Foster City, CA 94404 U.S.A

Attention: General Counsel Facsimile: (650) 522 - 5537

Medicines Patent Pool Chemin Louis – Dunant 17 1202 Geneva Switzerland Attention: General Counsel

Email: office@medicinespatentpool.org

Sub: Termination of Tenofovir Disoproxil Fumarate

Ref: Third Amended and Restated License Agreement dated September 22nd, 2015 (License Agreement) executed by and between Gilead Sciences, Inc., the Medicines Patent Pool and Hetero Labs Limited

Dear Sir/Madam,

I am writing to inform you that Hetero Labs Limited, Gilead Sciences, Inc., and Medicine Patents Pool executed the License Agreement dated September 22nd, 2015 for Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, Elvitegravir and Cobicistat, hereby enclosed under Annexure I to this Notice.

In accordance with Section 10.5 of the License Agreement, Hetero Labs Limited provides this Notice of termination of license solely for Tenofovir Disoproxil Fumarate (TDF), effective immediately.

We look forward to fruitful and collaborative relationship with Gilead Sciences, Inc. and the Medicines Patent Pool.

Yours Sincerely,

Hetero Labs Limited

Acknowledged and Accepted by

Gilead Science, Inc.

Medicines Patent Pool

Annexure I

Third Amended and Restated License Agreement dated September 22nd, 2015 (License Agreement) executed by and between Gilead Sciences, Inc., the Medicines Patent Pool and Hetero Labs Limited